Firms To Watch: Healthcare and life sciences

Sigma Legal specialises in technology and innovation law as well as in the life sciences and healthcare sectors; here it advises corporations, start-ups, non-profits, and organizations such as the World Health Organinzation.
The specialist boutique IPrime specialises in intellectual property and dispute resolution instructions from pharmaceutical, med- and biotech clients.

Healthcare and life sciences in Switzerland

Bär & Karrer Ltd.

Bär & Karrer Ltd. is a go-to counsel for Swiss and foreign life sciences companies, public and private institutions and subsidiaries of international groups, including hospitals, care homes and clinics. The group covers private and public M&A and capital markets transactions, patent litigation and other disputes. Internal investigations in the pharmaceutical industry are also handled. Markus Schott is a specialist in regulatory questions, while Markus Wang covers IP-law, R&D and marketing/distribution. Philippe Seiler is a key contact for transactions.

Practice head(s):

Markus Schott; Markus Wang

Other key lawyers:

Philippe Seiler; Raphael Wyss


‘Strong collaboration between the specialists in-house, but also between the offices located in the different language territories.’

‘Markus Wang demonstrates a very practice-oriented, hands-on and pragmatic way of thinking when it comes to finding solutions to the healthcare sector and its regulations. He has a deep understanding of the pharmaceutical market and its characteristics.’

‘Markus Schott manages to keep an overview of complex contractual constructions and at the same time does not lose sight of the essential aspects of life science regulations. He is passionate about his clients’ concerns and shows persistence in dealing with authorities until a positive outcome is found in the matter.’

Key clients



GSK (GlaxoSmithKline)

Glenmark Pharmaceuticals

Vir Biotech/Humabs Biomed

Novo Nordisk

Gedeon Richter

Galderma Skin Health S.A


Colosseum Dental Group

Work highlights

  • Successfully represented Sandoz in appeal proceedings before the Federal Administrative Tribunal.
  • Successfully represented Glenmark in patent litigation in Switzerland against Boehringer Ingelheim concerning the blockbuster product Spiriva before the Swiss Federal Patent Court and in appeal proceedings before the Swiss Federal Supreme Court.
  • Acted as legal advisor to Vifor Pharma on the sale of its OM Pharma business to Optimus Holding Ltd.


Homburger fields a team of ‘strong subject matter experts‘ across different specialisms: Dieter Gericke is a specialist in advising healthcare and life sciences clients on corporate law and transactions, while Andri Hess ‘provides strong support on IP litigation matters.Gregor Bühler covers regulatory aspects, and Marcel Dietrich is the name to note in competition and antitrust queries; together they head up the firm’s practice. Luca Dal Molin is sought after for data protection questions. Daniel Häusermann advises on financing transactions.

Other key lawyers:

Daniel Häusermann; Luca Dal Molin; Angelika Murer


‘Strong subject matter experts, practicable advice, pragmatic, nice to work with, great teamwork, sense of urgency, excellent associates.’

‘Andri Hess provides strong support on IP litigation matters. Depth of experience is great. Provides solid, commercial advice.’

‘Andri Hess and Angelika Murer provide excellent support.’

‘The Homburger team is very responsive and always giving us well-founded advice.’

‘I would recommend Andri Hess for his deep knowledge and understanding of the law and proceedings, his great preparation of arguments and briefs to be filed, the good discussions with him and his well-founded recommendations of how to proceed. Andri Hess always looks diligently into the details. We feel well-represented by Homburger.’

Key clients




Johnson & Johnson


Eli Lilly



Molecular Partners

Santhera Pharmaceuticals Holding

PPF Group

Vifor Pharma

ADC Therapeutics

Bristol Myers-Squibb

Edwards Lifesciences





Zur Rose Group



Atara Biotherapeutics






Covis Pharma

IMA Medtech


Addex Therapeutics

Strides Pharma Science

Tillotts Pharma

SERI Lugano


Work highlights

  • Advised Molecular Partners in connection with a collaboration with Novartis to develop DARPin® therapies designed for potential use against COVID-19.
  • Defending Sandoz before the Swiss Federal Patent Court against multiple preliminary injunction requests and infringement actions based on Fulvestrant patents.
  • Advised Vifor Pharma on due diligence review of Angion’s development activities and on the license agreement.

Kellerhals Carrard

Kellerhals Carrard impresses with ‘high analytical skills and great business acumen which make them a great team to work with.’ It regularly acts for pharma, life sciences and medtech companies as well as for doctors and hospitals. The group has considerable expertise in the regulatory space, compliance and investigations, as well as in related disputes, but also covers financing rounds and M&A transactions. Practice head Thomas Eichenberger is also well versed in tort and product liability law, competition law and contract law. Claudia Götz Staehelin is a specialist in contentious matters. Nicolas Mosimann and Beat Brechbuehl are the names to note in transactional queries. Oliver M. Brupbacherhas very profound knowledge in large-scale civil litigations.

Practice head(s):

Thomas Eichenberger

Other key lawyers:

Christoph Zimmerli; Claudia Götz Staehelin; Nicolas Mosimann; Beat Brechbuehl; Jean-Luc Chenaux; Frédéric Rochat; Oliver M. Brupbacher; Claudio Helmle


‘They stand out due to their precise approach to matters and their connection to people – they are people’s people. I would like to mention Claudia Götz Staehelin here.’

‘The healthcare and life sciences team of Kellerhals Carrard has a profound knowledge of the healthcare and life science law, they have a quick grasp and provide you with a thorough assessment which is to the point and comes in a timely manner.’

‘Thomas Eichenberger is in my view THE expert in Swiss healthcare and life sciences law, with broad and long-term experience in counselling and representing all kinds of clients in this field for decades. Thomas also knows the different stakeholders very well and can provide his clients with an assessment which is thorough and to the point.’

‘One of Kellerhals Carrard’s unique strengths is that they combine specialist dispute resolution and white-collar/internal investigation experience with extensive international business and crisis management experience: the understanding of the needs of in-house counsels is extremely high in Kellerhals. Also definitely worth mentioning is the profound litigation experience of Pascal Grolimund and Olivier Mosimann, who are extremely experienced and very strong in this area.’

‘Claudia Götz Staehelin possesses the – for external counsels – rare combination of business experience and significant company insights and broad and long-term dispute resolution expertise. Claudia is an expert in dispute resolution in domestic and cross-border matters and has also extensive experience in handling large internal investigations in an international context.’

‘Claudia Götz-Stähelin and Oliver Brupbacher have very strong expertise and experience in the life science sector. Their responsiveness and solution-oriented approach together with a very collaborative approach just makes it fun to work with them!’

‘Nicolas Mosimann: Very dedicated and motivated. High level of expertise. Always flexible and pragmatically focused on the client’s interests. Solution-oriented. High level of social competence.

‘Thomas Eichenberger has many years of experience in the healthcare sector and is an authority in the field. He has a very good network and knows the needs of the industry.’

Key clients

Moderna Inc./Moderna Switzerland GmbH

Gilead Sciences Switzerland Sàrl

Roche Pharma (Schweiz) AG

MoonLake Immunotherapeutics AG

Actelion Pharmaceuticals

Eli Lilly (Suisse) S.A.

Vifor Pharma AG

AdVita Lifescience GmbH


Fischer Spindle Group



Gebro Pharma AG

Work highlights

  • Advised Moderna on COVID-19 vaccine, including legal and regulatory advice related to the establishment of its supply chain for its COVID-19 vaccine, Swiss launch preparations, trade and commercial matters, as well as healthcare compliance and regulatory aspects.
  • Advised Gilead on regulatory and reimbursement questions regarding the medicinal product Remdesivir, indicated to treat COVID-19.
  • Advised MoonLake on the incorporation, the company setup (including employment agreements and employee participation plans), data privacy and the Series A financing.


Pharmaceutical and life sciences companies, entrepreneurs/start-ups as well as private equity and individual investors regularly turn to the team at VISCHER for advice. Areas of expertise are regulatory matters, including compliance and administrative procedures, and patent cases in the biotech and pharmaceutical sector. Furthermore, it is also involved in IPOs, financing rounds and M&A deals. Stefan Kohler, a life sciences IP specialist, and transaction expert Matthias Staehelin lead the practice. Christian Wyss is a key contact for start-ups.

Other key lawyers:

Christian Wyss; Damien Conus; Vincent Reardon


‘Vischer provides integrated support to biotech firms with in-depth knowledge of this business area. Quality, reliability, broad know-how.’

Key clients


Numab Therapeutics



Haya Therapeutics





Trustar Capital

Noema Pharma


Synendos Therapeutics

Polyneuron Pharmaceuticals


T3 Pharmaceuticals


ClearView Healthcare Partners


Sonnet BioTherapeutics, Inc.

Labcorp Drug Development (formely Covance)


CTI Vascular

Work highlights

  • Advised NBE-Therapeutics and its shareholders on sale to Boehringer Ingelheim for €1.18bn.
  • Advised Numab Therapeutics on global co-development and regional licensing agreement with Kaken Pharmaceutical Co., Ltd. (Tokyo, Japan) for Numab Therapeutics’s novel multispecific anti-inflammatory drug.
  • Advised Novartis on a collaboration agreement and option to acquire Zurich based start-up Cellerys.

Bratschi Ltd

With deep regulatory experience, Bratschi Ltd is noted for being ‘flexible‘ and having the ‘high capacity to think out-of-box.‘ The team acts for therapeutic products manufacturers, laboratory services and medical services providers across the full range of matters, including litigation, advertising, commercial cooperation agreements and compliance matters. The team is jointly led by Felix Kesselring, who has a ‘precise and analytic approach‘, and Ursula Eggenberger Stöckli, who is also a pharmacist. Marco Rizzi is also noted.

Practice head(s):

Felix Kesselring; Ursula Eggenberger Stöckli

Other key lawyers:

Marco Rizzi


‘Very extensive knowledge and experience in the life sciences field support is always of great value.’

‘I consider Felix Kesselring as an excellent practitioner with great expertise and a calm, but precise and analytic approach.’

‘Felix Kesselring is very knowledgeable and pragmatic in advising on complicated situations as well as day-to-day activities.’

‘The firm appears to us to be very agile, uncomplicated, multicultural and solution-oriented. They clearly benefit from their vast experience, their network within the group and also different levels of competencies. High ability to ensure the proper level of support in any situation.’

‘Felix Kesselring has outstanding practical and academic knowledge about legal healthcare issues. His practical industry experience makes him one of the few people to go to in healthcare and life sciences matters.’

‘Deep understanding of the pharmaceutical market combined with legal expertise. Compared to other firms we have got many inputs, how we can work and not just that it is not possible. The response time was always very short and the answers very useful.’

‘Flexible and high capacity to think out-of-box.’

‘Great experience in law and in pharma regulations.’

Key clients

Gilead Sciences Switzerland LLC

Smith & Nephew Orthopaedics Ltd.

Sigma Aldrich Production GmbH, a subsidiary of Merck KGaA

CSL Behring Ltd.

Synaffix BV

IGEN Biolab Group Ltd.

Kantonsspital St. Gallen

Spitalregion Fürstenland-Toggenburg

Oertli-Instrumente AG

Work highlights

  • Advised Gilead Sciences Switzerland LLC on early access of Remdesivir against Covid-19 in Switzerland.
  • Advised Smith & Nephew Orthopaedics on several liability claims.
  • Advised CSL Behring Ltd. on the implementation of a production plant for immunoglobulins in Switzerland.


CMS von Erlach Partners Ltd. covers a range of life sciences and healthcare matters and is particularly well-positioned in cross-border instructions. The team has know-how in regulatory frameworks for therapeutic products, laboratory services and medical service providers; administrative and court proceedings; commercial cooperation agreements; compliance and advertising. Patrick Sommer, who leads the practice together with senior associate Marion Wyler also offers competition law experience. The practice is increasingly active in projects regarding medical health applications.

Practice head(s):

Patrick Sommer; Marion Wyler

Key clients

Bayer (Switzerland) AG

synlab Suisse SA (and its subsidiaries)

Kieser Training AG

Mobile Health AG

Work highlights

  • Advising and representing a medical devices company in a disclosure procedure to various European authorities of a potential non-compliance regarding authorizations.
  • Advising and representing Bayer Schweiz AG in proceedings before the Swiss Federal Supreme Court regarding alleged vertical price-fixing of drugs traded over-the-counter.
  • Advised Bruker on the acquisition of PMOD Technologies LLC, a provider of research-use-only software for preclinical and molecular imaging.

Lenz & Staehelin

Lenz & Staehelin‘s practice comprises specialists from different areas: Thierry Calame is a key contact in IP- and regulatory related queries, while Harold Frey has considerable know-how in life sciences disputes. The corporate and M&A-front is also well covered with names such as Andreas Rötheli and Guy Vermeil. The instructions come from a range of clients, such as pharmaceuticals, biotechnology, medical devices, diagnostics and pharmaceutical distribution companies, as well as other organisations such as healthcare providers and academic institutions. Lara Dorigo left the firm in early 2022.


‘The team is resourceful, reliable, responsive, collaborative, competent, skilled.’

‘We have worked closely with Thierry Calame and were very happy with the support provided, in-depth knowledge, expertise, collaborative approach, strategic thinking and creativity.’

‘The team has the size and skilled members that it takes to be able to find the right lawyers for each task.’

‘Peter Ling has the required knowledge about his area of legal expertise, but most importantly he also understands the business that he is advising on. His conclusions are so accurate thanks to his business mindset.’

‘The team is knowledgeable in life science topics and is internationally well connected with various experts in the life science areas, in particular when concerning corporate and commercial issues.’

‘The individuals are knowledgeable in life science topics and can bring cumulatively many years of experience on which solutions can be proposed and implemented.’

‘Responsible, considerate, good experts.’

Key clients

Abbott Laboratories

Alcon Inc.

Alpha Health Group

Altitude Management

Bain Capital Private Equity


Chord Therapeutics


Keri Medical


Manufacture Modules Technologies

Mark Bischof and Rabah Nedir (owners of the Ardentis group)


Merck & Co., Inc.

Morgan Stanley

NovImmune SA

Obseva SA


Revance Therapeutics, Inc.

Surveyor Capital

swiss smile Schweiz AG

The Carlyle Group

Work highlights

  • Advised the underwriters JP Morgan/Morgan Stanley, Cowen and Credit Suisse on the July 2021 IPO of SOPHiA GENETICS SA.
  • Advising Pfizer on proceedings before the Supreme Court related to price recommendations related to the drug Viagra.
  • Advising Abbott in multi-jurisdictional trade mark litigation proceedings, leading to a landmark decision of the Swiss Supreme Court.

MLL Legal

After its merger, MLL Legal‘s life sciences & healthcare practice is now headed up by Simon Holzer and Nicola Benz. It ‘stands out for its comprehensive and interdisciplinary approach in finding tailor-made solutions‘ and offers clients from the pharmaceutical and medical devices field legal support. The team is well versed in IP-related matters, dispute resolution and contracts. Kilian Schärli is noted for his know-how in blockchain pharmaceutical cases. Ulrike Ciesla is a key contact in patent matters. Associate Louisa Galbraith is a ‘rising star.’

Practice head(s):

Nicola Benz; Simon Holzer


‘Simon Holzer inspires confidence with his leadership. Ulrike Cielsa is technically excellent and always on top of the detail.’

‘Premier IP practice, particularly in the life sciences space. Intimate knowledge of the ins and outs of IP practice and procedure in Switzerland. Valuable strategic advice.’

‘Simon Holzer is a brilliant legal mind and an absolute pleasure to work with. Very experienced practitioner whom we trust wholly.’

‘Louisa Galbraith is a rising star and one to watch in the near future.’

‘Kilian Schärli is recognised as a skilled and driven individual and as a leader in his field of expertise – which is why he clearly stands out as the lead partner. Kilian Schärli is really smart and committed. He always goes the extra mile for us and is available 24/7. He is down to earth and has an extraordinary sense for commercially good solutions. It is indeed a true pleasure to work with him.’

‘Nicola Benz has a unique and exceptionally productive way to work with start-up companies. She is very practical and yet diligent to keep the challenging balance between founders, owners, management and investors.’

‘Simon Holzer is a really impressive lawyer who leads an excellent team (Louisa Galbraith and others) and has consistently delivered outstanding results. He is highly skilled and experienced and immediately gives the impression that the case is in good hands. He is enthusiastic and quick to get up to speed with the details of the case. He delivers clear, concise and commercial advice and has always been a pleasure to work with.’

‘The team has a great knowledge of practice and procedure before the Swiss courts and uses this to provide timely commercial advice. The team is very experienced in working as part of an international team on multi-jurisdictional cases and, as well as managing cases in Switzerland, contributes to the development of the case internationally. The team is very responsive and is able to provide straightforward explanations of litigating in Switzerland.’

Key clients

Alpex Pharma SA

AstraZeneca AB (Sweden), AstraZeneca (Switzerland) AG


Axapharm AG

Bayer Pharma AG (Germany), Bayer Intellectual Property AG (Germany)

Bayer Consumer Care AG (Switzerland), Bayer (Schweiz AG) (Switzerland)

Baxter Ltd

Becton Dickinson Company

Bioeq AG

Boehringer Ingelheim Pharma GmbH & Co. KG


Cellprotect Holding AG

cereneo Schweiz AG and cereneo International AG

Eli Lilly

Eurospine, The Spine Society of Europe

Exact Sciences International Sàrl

Gilead Sciences, Inc.

H. Lundbeck A/S (Denmark); Lundbeck Schweiz AG (Switzerland)

Implantec Schweiz GmbH


Intuitive Surgical

Kantonsspital St. Gallen (KSSG)

Lipomed AG

Lusaria AG

MaKe WeBo AB


Mundipharma Medical Company, Mundipharma AG and other companies of the Mundipharma group of companies


Psychiatrische Dienste Aargau AG

RDP Pharma AG


Shockwave Medical

Spital Männedorf AG

Swiss Cosmetic Association (SKW)

Swiss Medtech (Swiss Medical Technology Association)


ViiV Healthcare

Visiomed Laboratories

Work highlights

  • Successfully represented Astra Zeneca in a patent dispute concerning Astra Zeneca’s blockbuster breast cancer medicament Faslodex® before the Federal Patent Court and the Federal Supreme Court.
  • Rendered an expert opinion for Swiss medical technology association SWISS MEDTECH on incentive taxes on VOCs in disinfectants.
  • Successfully represented ImplanTec GmbH, a family-owned manufacturer of artificial hip joint endoprostheses, in Switzerland’s IP impact case of the year 2020/2021 before the Federal Patent Court and the Federal Supreme Court.

Schellenberg Wittmer Ltd

Schellenberg Wittmer Ltd has core capabilities in representing life sciences clients in disputes as well as advising them on corporate and commercial aspects, such as licensing deals, joint ventures and M&A transactions. The team is led by Philipp Groz who also forms an experienced IP duo with Lorenza Ferrari Hofer.

Practice head(s):

Philipp Groz

Other key lawyers:

Lorenza Ferrari Hofer; David Mamane; Pascal Hubli

Baker McKenzie

Baker McKenzie can showcase a broad client portfolio that encompasses companies from the pharmaceutical, biotech, health-tech and medical devices industries, as well as hospitals, laboratories, insurances and food manufacturers. It regularly acts in cross-border compliance programs, transactions and collaboration agreements in which the international network adds value. Matthias Courvoisier leads the practice, which also includes employment specialists Peter Reinert and Serge Pannatier. Senior associate Julia Schieber ‘catches every angle and detail.’

Practice head(s):

Matthias Courvoisier

Other key lawyers:

Peter Reinert; Serge Pannatier; Julia Schieber


‘Julia Schieber is truly outstanding. She is smart, quickly understood the issues and interplays between several agreements, catches every angle and detail, was always fully committed, never dropped the ball on any matter and worked super hard to get the deal over the finish line in a short period of time.’

‘Baker McKenzie acts highly efficiently to solve our legal issues, contracting, strategy and/or negotiations. This advice and service is performed depending on our need either by a highly professional single lawyer or a broader team.’

‘Julia Schieber is a highly engaged and experienced legal advisor with excellence in contracting and negotiating complex licensing contracts with strong and complex IP topics.’

‘Julia Schieber is a highly skilled, hard-working, thorough, reliable, strong negotiator and fun person to work with. Accessible literally around the clock.’

Key clients



Actelion Pharmaceuticals AG

Adagene AG

Allecra Therapeutics AG

Argenx SE

Baitella Holding AG

Basilea Pharmaceutica AG

Bausch Health Corporation

Baxalta Inc

Becton Dickinson

Cassiopea SpA


Cell Medica Ltd

Cosmo Pharmaceutical NV

Curasept A.D.S. S.r.l.



HBM Partners Ltd

Implantica AG

Mérieux Equity Partners

NLS Pharma AG




Sanofi Aventis (Suisse) SA


Sonova AG


The International Federation of Pharmaceutical Manufacturers & Associations

Zur Rose Group

Work highlights

  • Advised CureVac on a number of strategic collaboration agreements with healthcare companies such as GSK and Bayer relating to the research, development and manufacture of vaccines (including for COVID).
  • Acted as legal adviser to Implantica AG on a medtech IPO on Nasdaq First North Premier.
  • Advised Basilea Pharmaceutica Ltd. on its capital increase from authorized capital and the related share placement in an accelerated book-building procedure and on the completion of its repurchase offer for existing convertible bonds due 2022 and the issuance of new convertible bonds due 2027.

BianchiSchwald LLC

BianchiSchwald LLC‘s pillars are healthcare companies as well as start-ups, entrepreneurs and investors from the healthcare and med/biotech industry. The team covers a good range, including obtaining operating approvals, transactions, public procurement and disputes. Practice head Marc Metzger is an ‘outstanding negotiator‘. Since publication, Thomas Goossens left the firm.

Practice head(s):

Marc Metzger

Other key lawyers:

Hans-Peter Schwald; Andreas Suter; Thomas Schmid


‘The firm’s healthcare and life science practice group is very experienced and very skilled in their fields of business. They have a strong in-depth legal and market knowledge of the healthcare sector. They have vast know-how in national health care regulations, health insurance and public procurement law issues including also procedural aspects and relevant public sector law aspects. They think very entrepreneurially and are accurate and efficient at the same time.’

‘Hans-Peter Schwald is a very valuable strategic adviser to us. He is extremely committed and absolutely brilliant strategically and concentrates on what is essential. He is a leading figure in the business lawyers’ industry.’

‘Marc Metzger is a senior figure and an excellent practitioner. He knows everything about, inter alia, health care regulations, health care insurance as well as health care financing contracts. Marc is very skilled and an outstanding negotiator. Also, he is extremely responsive and flexible.’

‘Andreas Suter has vast knowledge about the healthcare legislation in Switzerland. He is very skilled and works highly efficiently.’

Key clients

VAMED Management und Service Schweiz AG

Rehaklinik Seewis AG

Rehaklinik Dussnang AG

Calypso Biotech SA

Correvio International Sàrl

WS Audiology AG

VAMED Health Project Schweiz AG

Kreos Capital

Omega Fund Management LLC

Rehaklinik Zihlschlacht AG


Pestalozzi‘s client portfolio features manufacturers and distributors of pharmaceutical products and medical devices, service providers, investors, and NGOs. Led by Christian Roos and Franz Schubiger, the team advises on M&A, PE and VC-transactions in the life sciences area, but also on R&D, cooperation and licensing matters. It also offers support in compliance, regulatory and disputes. Its IP offering was bolstered with the arrival of Lara Dorigo from Lenz & Staehelin in January 2022.

Other key lawyers:

Sarah Drukarch; Lara Dorigo

Key clients

Akorn Pharmaceuticals

Astellas Pharma Europe, belonging to Astellas Pharma, Inc.

European Investment Bank (EIB)

GE Healthcare/GE Medical Systems (Switzerland)

Gilead Sciences/Kite Pharma

Johnson & Johnson

Johnson & Johnson Innovation – JJDC, Inc.

Nutriathletic AG

Merck KGaA

University Hospital Zurich (USZ)

Zimmer Biomet (NYSE: ZBH)

Work highlights

  • Advising the European Investment Bank on a €20m financing agreement with BioVersys.
  • Advising H.C. Wainwright & Co in $20m underwritten offering and concurrent private placement in ObsEva SA.
  • Advising Johnson & Johnson on a broad range of Swiss legal and tax matters relating to its subsidiaries operating in and from Switzerland.

Wenger Vieli Ltd

The team at Wenger Vieli Ltd is regularly instructed by pharmaceutical, biotech and medical device companies in related matters. Its scope covers market access, pricing and reimbursement, marketing authorisations, data protection, clinical and other research, as well as product liability. The group frequently works closely with other departments for interdisciplinary matters. The team around Frank Scherrer also includes associate Marcel Boller.

Practice head(s):

Frank Scherrer

Other key lawyers:

Beat Speck; Marcel Boller

Work highlights

  • Advised several pharmaceutical companies on market access procedure for Covid-19 vaccines and therapies.
  • Advising affected companies in newly developed Health Technology Assessment procedure of Federal Office of Public Health (reassessment of reimbursement status), including appeal proceedings.
  • Defending a pharmaceutical company in product liability lawsuits.

Wenger Plattner

Wenger Plattner showcases ‘strong experience and capabilities across life sciences and healthcare.‘ The team handles a range of related matters for hospitals, pharmaceutical, biotech and insurance companies, healthcare bodies and organisations as well as individuals. Practice head Carlo Conti advises on governmental and administrative law, while Oliver Künzler‘s focus lies on the transactional side.

Practice head(s):

Carlo Conti

Other key lawyers:

Oliver Künzler


‘Flexible and well-informed team.’

‘Very strong know-how of the healthcare industry. Excellent client knowledge. Strong strategic consulting capability.’

‘Excellent to deal with. Deep know-how. Excellent collaboration.’

‘Strong experience and capabilities across life sciences and healthcare. Excellent support for large and smaller/start-up companies. Billing adapted to company size/possibilities. Also strong transaction/M&A capabilities.’

‘Carlo Conti: outstanding healthcare and political insights, deep experience across healthcare and life sciences.’

‘Oliver Künzler: great experience for business transactions, M&A, contracting, etc.’

Key clients

Zurzach Care AG (former RehaClinic AG)

Schweizerische Diabetes-Stiftung

Viollier AG

Casavita Stiftung


Medgate AG

Universitäre Psychiatrische Kliniken Basel

Universitätsspital Zürich

Caru AG

Work highlights

  • Advising SWICA on all corporate matters as well as with respect to telemedicine and related licensing issues in order to receive the necessary marketing authorisation from the relevant authorities.
  • Advised the USZ innovation management team in matters relating to innovation projects, the creation of start-ups, and the strategic initiative called ‘health innovation hub’.
  • Advised IQVIA and other companies in connection with the organisation and negotiation of CTAs with hospitals in Switzerland as well as related legal clarifications, in particular in the area of regulatory law.